MDVP for adjuvanted pandemic vaccines
By Soren Spanner on Friday, 27 November 2009
Posted in Service delivery
Replies 1
Likes 0
Views 3.9K
Votes 0
Dear all, I have a question on multi-dose vial policy for adjuvanted pandemic vaccines. We received Focetria, MF59C.1 adjuvanted vaccine in 10-dose presentations which contains thimerosal as a preservative. Can WHO multi-dose vial policy be applied to this vaccine (to use it four weeks after the first dose has been drawn from the vial)? Best regards, Bernard Kaic National EPI manager Croatian Institute of Public Health Department of infectous disease epidemiology Rockefellerova 7 HR-10000 Zagreb Croatia Tel: +385 1 4683 004 Fax: +385 1 4683 877 E-mail: [email=bernard.kaic@hzjz.hr]bernard.kaic@hzjz.hr[/email] www.hzjz.hr
Eric Marie Jean Laurent from WHO responds to Bernard Kaic's question: The manufacturer has confirmed that Focetria contains the regular amount of thiomersal. However, at this stage, as we are still working on the review of the Summary of Product Characteristics, and basically the stability aspects, we would recommend NOT to apply the MDVP policy until we get more information. We expect to get some more details by next week.
Moderator
·
14 years ago
·
0 Likes
·
0 Votes
·
0 Comments
·
View Full Post